The report finds that the European and the US biotechnology industries both have around 2000 companies, but the US sector employs nearly twice as many people, spends around three times as much on research and development, has twice the number of employees involved in research and development, raises over twice as much venture capital, and has access to 10 times as much debt finance. It earns twice as much revenue.